CD8A and neoplasm: We observed a significantly lower CD8+/FOXP3+ ratio in patients with tumours containing activating mutations of the Wnt pathway compared with wild-type tumours (2.65 ± 1.2 versus 6.08 ± 5.0, P = 0.043, Mann–Whitney U test) (Figure 5C).